Your browser doesn't support javascript.
loading
Haematopoietic stem and progenitor cells from human pluripotent stem cells.
Sugimura, Ryohichi; Jha, Deepak Kumar; Han, Areum; Soria-Valles, Clara; da Rocha, Edroaldo Lummertz; Lu, Yi-Fen; Goettel, Jeremy A; Serrao, Erik; Rowe, R Grant; Malleshaiah, Mohan; Wong, Irene; Sousa, Patricia; Zhu, Ted N; Ditadi, Andrea; Keller, Gordon; Engelman, Alan N; Snapper, Scott B; Doulatov, Sergei; Daley, George Q.
Afiliação
  • Sugimura R; Stem Cell Transplantation Program, Division of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
  • Jha DK; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Han A; Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
  • Soria-Valles C; Manton Center for Orphan Disease Research, Boston, Massachusetts 02115, USA.
  • da Rocha EL; Stem Cell Transplantation Program, Division of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
  • Lu YF; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Goettel JA; Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
  • Serrao E; Manton Center for Orphan Disease Research, Boston, Massachusetts 02115, USA.
  • Rowe RG; Stem Cell Transplantation Program, Division of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
  • Malleshaiah M; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Wong I; Stem Cell Transplantation Program, Division of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
  • Sousa P; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Zhu TN; Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
  • Ditadi A; Manton Center for Orphan Disease Research, Boston, Massachusetts 02115, USA.
  • Keller G; Stem Cell Transplantation Program, Division of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
  • Engelman AN; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Snapper SB; Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
  • Doulatov S; Manton Center for Orphan Disease Research, Boston, Massachusetts 02115, USA.
  • Daley GQ; Stem Cell Transplantation Program, Division of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Nature ; 545(7655): 432-438, 2017 05 25.
Article em En | MEDLINE | ID: mdl-28514439
ABSTRACT
A variety of tissue lineages can be differentiated from pluripotent stem cells by mimicking embryonic development through stepwise exposure to morphogens, or by conversion of one differentiated cell type into another by enforced expression of master transcription factors. Here, to yield functional human haematopoietic stem cells, we perform morphogen-directed differentiation of human pluripotent stem cells into haemogenic endothelium followed by screening of 26 candidate haematopoietic stem-cell-specifying transcription factors for their capacity to promote multi-lineage haematopoietic engraftment in mouse hosts. We recover seven transcription factors (ERG, HOXA5, HOXA9, HOXA10, LCOR, RUNX1 and SPI1) that are sufficient to convert haemogenic endothelium into haematopoietic stem and progenitor cells that engraft myeloid, B and T cells in primary and secondary mouse recipients. Our combined approach of morphogen-driven differentiation and transcription-factor-mediated cell fate conversion produces haematopoietic stem and progenitor cells from pluripotent stem cells and holds promise for modelling haematopoietic disease in humanized mice and for therapeutic strategies in genetic blood disorders.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Células-Tronco Hematopoéticas / Diferenciação Celular / Linhagem da Célula / Células-Tronco Pluripotentes Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Células-Tronco Hematopoéticas / Diferenciação Celular / Linhagem da Célula / Células-Tronco Pluripotentes Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article